Q32 Bio Inc. (LON:0T6G)
London · Delayed Price · Currency is GBP · Price in USD 3.591
+0.031 (0.88%)
Feb 12, 2026, 3:28 PM GMT
Q32 Bio Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
26
Market Cap
34.59M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | -6.65M | -9.86M | - |
| Dec 31, 2022 | 3.21M | -30.76M | -90.56% |
| Dec 31, 2021 | 33.97M | 31.27M | 1,157.25% |
| Dec 31, 2020 | 2.70M | 1.04M | 62.18% |
| Dec 31, 2019 | 1.67M | -3.66M | -68.70% |
| Dec 31, 2018 | 5.32M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Kooth | 66.34M |
| hVIVO | 54.47M |
| AOTI, Inc. | 46.61M |
| Ondine Biomedical | 1.18M |
Q32 Bio News
- 2 months ago - Insider Sell: Lee Kalowski Sells Shares of Q32 Bio Inc (QTTB) - GuruFocus
- 2 months ago - Q32 Bio Sells Complement Inhibitor ADX-097 To Akebia Therapeutics - Nasdaq
- 2 months ago - Dow Dips 200 Points; Q32 Bio Shares Jump - Benzinga
- 2 months ago - Why Is Small-Cap Q32 Bio Stock Soaring On Monday? - Benzinga
- 2 months ago - Why Is Small-Cap Q32 Bio Stock Soaring On Monday? - Benzinga
- 2 months ago - Q32 Bio Sells Complement Inhibitor ADX-097 - PRNewsWire
- 3 months ago - Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 4 months ago - Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata - PRNewsWire